What is Novocure?
Novocure is at the forefront of developing and commercializing Tumor Treating Fields (TTFields), a novel therapeutic approach aimed at improving outcomes for patients battling some of the most challenging forms of cancer. The company's commercialized products are approved in select regions for treating adult glioblastoma and malignant pleural mesothelioma in the U.S. Novocure's commitment to expanding the application of TTFields is evident through its extensive clinical trials investigating the therapy's efficacy across a spectrum of cancers, including brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Headquartered in Jersey, with significant operations in the U.S. and international offices in Germany, Switzerland, Japan, and Israel, Novocure is strategically positioned to address a global unmet need in oncology.
How much funding has Novocure raised?
Novocure has raised a total of $708M across 3 funding rounds:
Stock Offering
$158M
Debt
$150M
Debt
$400M
Stock Issuance/Offering (2015): $158M with participation from Undisclosed
Debt (2018): $150M led by BioPharma Credit PLC
Debt (2024): $400M supported by Pharmakon Software
Key Investors in Novocure
BioPharma Credit PLC
BioPharma Credit PLC is a specialist provider of debt financing solutions to the global biopharmaceutical industry. They focus on providing flexible and tailored credit facilities to support the development and commercialization of innovative therapies.
Pharmakon Software
Pharmakon Software GmbH specializes in omnichannel CRM and digital sales solutions tailored for the pharmaceutical and life sciences sectors, indicating a strategic interest in companies that can benefit from enhanced digital engagement and operational efficiency in their commercialization efforts.
Undisclosed Investors
What's next for Novocure?
The recent major strategic investment signifies a critical juncture for Novocure, likely enabling the acceleration of its clinical development pipeline and the expansion of its commercial reach. This infusion of capital, particularly in the context of enterprise-level funding, suggests confidence from investors in Novocure's TTFields technology and its potential to disrupt current cancer treatment paradigms. The company is expected to leverage this financial backing to advance its ongoing trials, potentially pursue regulatory approvals in new indications and geographies, and further scale its operational infrastructure. This strategic financing positions Novocure to continue its mission of extending survival for patients with aggressive cancers.
See full Novocure company page
